%0 Journal Article %T Ceritinib-related interstitial lung disease improving after treatment cessation without recurrence under either crizotinib or brigatinib: a case report %A Bender, Laura %A Meyer, Guillaume %A Quoix, Elisabeth %A Mennecier, Bertrand %J Annals of Translational Medicine %D 2019 %B 2019 %9 %! Ceritinib-related interstitial lung disease improving after treatment cessation without recurrence under either crizotinib or brigatinib: a case report %K %X Anaplastic lymphoma kinase inhibitors (ALKi) like ceritinib are considered standard for front-line treatment of non-small cell lung cancers (NSCLC) harboring a translocation of the anaplastic lymphoma kinase (ALK) gene. We report herein a case of interstitial lung disease (ILD) that developed following a 7-month ceritinib treatment without recurrence under either crizotinib or brigatinib, two others ALKi. %U https://atm.amegroups.org/article/view/23669 %V 7 %N 5 %P 106 %@ 2305-5847